[Gilead Sciences Q3 2026 Earnings Call] Gilead Lifts 2026 Sales Outlook by $900 Million as HIV Sales Jump 18%, but Flags $1.5 Billion BIKTARVY IRA Hit in 2028

Gilead Sciences raised its 2026 sales forecast by $900M after Q3 revenue grew 13% YoY to $8.3B, driven by 18% HIV sales growth. Non-GAAP EPS rose 3.2% YoY to $2.55. The company flagged a $1.5B revenue hit in 2028 from Medicare price negotiations on BIKTARVY. Management expects HIV revenue growth in 2028 despite the headwind.

Original reporting
Published Oct 29, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$GILDNeutralHigh
01

Why it matters

The guidance raise suggests continued revenue momentum, yet the $1.5B Medicare pricing headwind could compress margins and affect valuation.

02

Market read

Investors will reprice Gilead's stock based on the net effect of higher sales outlook versus regulatory cost exposure.

03

What to watch

Upcoming FDA decisions on oral HIV regimens and CAR‑T therapy could provide additional upside not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Gilead's Q3 earnings are the first release of its 2026 guidance and the first detailed IRA impact disclosure.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead reported Q3 2026 results, raised full-year sales guidance by $900M and disclosed a $1.5B IRA impact on BIKTARVY revenue in 2028.

Expected impact

mixed pressure as investors weigh higher sales guidance against the $1.5B Medicare pricing headwind.

Evidence & confidence

Strong quarter and raised guidance are bullish, but the disclosed regulatory cost is material and may weigh on the stock.

Market effects

Highlights potential IRA pricing pressure on other HIV/rare disease biotech firms.

U.S. biotech sector may see modest volatility as investors reassess Medicare pricing risk.

Limited to companies with similar Medicare exposure; broader market impact minimal.

Counterpoint

The IRA hit may be overstated; Gilead's diversified pipeline could offset the cost, supporting a buy.

Key entities

  • Gilead Sciences

    US‑listed biopharma reporting earnings and guidance.

  • BIKTARVY

    Flagship HIV therapy subject to Medicare price negotiation.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.